Brief: Otsuka Pharmaceutical Announces Ulefnersen Early Access Program For Eligible People Living With FUS-ALS
Brief: Otsuka Pharmaceutical Says Phase 3 Fusion Results For Ulefnersen Met Primary Endpoint
Zipalertinib Plus Chemotherapy Demonstrates 6-Month Median Progression-Free Survival Benefit In Rezilient3 Phase 3 Trial In First-Line Egfr Exon 20 Insertion Mutation Non-Small Cell Lung Cancer
Climb Bio rises after early-stage data for kidney disease drug
Vera rises on early kidney function data in FDA review
Zipalertinib Plus Chemotherapy Meets Primary Pfs Endpoint In Planned Interim Analysis Of Phase 3 Rezilient3 Trial
Table: Otsuka Holdings -2026 group forecast(IFRS)
Table: Otsuka Holdings 6-MTH group results (IFRS)
2026 6-month group forecast(IFRS)
US FDA approves Vera's kidney disease drug (updated)
US FDA approves Vera's kidney disease drug
Otsuka Reports Positive Phase 3 Visionary Two-Year Egfr Results For Voyxact In Igan
Advisory: Alert on Otsuka Pharmaceutical wrongly tagged to Otsuka Corp withdrawn
Brief: Otsuka Initiates Rolling Submission Of sBLA To FDA For Voyxact Traditional Approval
Otsuka says kidney disease drug preserves function in late-stage study
Table: Otsuka Holdings -Q1 group results (IFRS)
Otsuka Pharmaceutical To Acquire Transcend Therapeutics, Pay $700 Million To Shareholders Upon Acquisition
To Buy Back Up To 1.33% Of Own Shares Worth 50 Billion Yen
Table: Otsuka Holdings -2025 group results (IFRS)